BoomRay Pharmaceuticals and Novartis Forge a Landmark Global Partnership in Radioligand Therapy
In a significant development poised to transform cancer treatment, BoomRay Pharmaceuticals Co., Ltd., a leading clinical-stage biotechnology firm, has announced the establishment of an exclusive global licensing agreement with Novartis Pharma AG. This strategic partnership focuses on an undisclosed preclinical radioligand therapy (RLT) asset, combining BoomRay's innovative research capabilities with Novartis's extensive experience in the oncology sector.
The collaboration is set to enhance the discovery and development processes for radioligand therapies, a cutting-edge approach in precision medicine aimed at improving both diagnostics and treatment for cancer patients. According to the terms of the agreement, BoomRay is positioned to receive up to $900 million, which includes an upfront payment, various milestone payments linked to development and regulatory success, as well as potential royalties from future global sales of the therapeutic asset.
BoomRay’s CEO, Bo Shan, expressed enthusiasm over the partnership, stating, "We are honored and excited to enter into this agreement with Novartis, a recognized global leader in radioligand therapies, with an exceptional track record in delivering transformative medicines to patients. This agreement marks a significant milestone for BoomRay and is a strong validation of our discovery and development capabilities."
The RLT approach focuses on targeting cancer cells with radioactive compounds, believing this can lead to breakthroughs in cancer care. This innovative therapy has indeed become an important frontier in oncology, with its potential to provide targeted therapies, which can minimize side effects commonly associated with traditional chemotherapies.
Shiva Malek, Global Head of Oncology at Novartis, noted, "Radioligand therapies represent an important frontier in oncology, and at Novartis, we remain focused on driving breakthrough science that can expand their potential for patients. Our agreement with BoomRay complements our growing radioligand therapy portfolio and reflects our strategy of combining external innovation with our cutting-edge research and development capabilities."
This partnership has the potential to not just accelerate the development of the new asset but also to pave the way for emerging therapies that can significantly impact clinical outcomes for cancer patients globally. As both BoomRay and Novartis embark on this exciting journey, the collaboration is expected to open new avenues for innovative treatment solutions, progressively aiming to address the critical unmet needs in oncology.
About BoomRay Pharmaceuticals Co., Ltd.: BoomRay is dedicated to pioneering radioligand therapies that address critical gaps in cancer treatment. Its core competencies encompass candidate discovery, radiochemistry, and clinical translation, all aimed at developing first-in-class or best-in-class treatment options for various cancer types. With a strong leadership and scientific team, BoomRay aspires to bring forth novel solutions that significantly improve patient outcomes around the world. The integration of expertise from Novartis enhances their mission and represents a hopeful future for oncology treatment options.
For more information about BoomRay Pharmaceuticals, visit http://www.boomray.com.
The collaboration is set to enhance the discovery and development processes for radioligand therapies, a cutting-edge approach in precision medicine aimed at improving both diagnostics and treatment for cancer patients. According to the terms of the agreement, BoomRay is positioned to receive up to $900 million, which includes an upfront payment, various milestone payments linked to development and regulatory success, as well as potential royalties from future global sales of the therapeutic asset.
BoomRay’s CEO, Bo Shan, expressed enthusiasm over the partnership, stating, "We are honored and excited to enter into this agreement with Novartis, a recognized global leader in radioligand therapies, with an exceptional track record in delivering transformative medicines to patients. This agreement marks a significant milestone for BoomRay and is a strong validation of our discovery and development capabilities."
The RLT approach focuses on targeting cancer cells with radioactive compounds, believing this can lead to breakthroughs in cancer care. This innovative therapy has indeed become an important frontier in oncology, with its potential to provide targeted therapies, which can minimize side effects commonly associated with traditional chemotherapies.
Shiva Malek, Global Head of Oncology at Novartis, noted, "Radioligand therapies represent an important frontier in oncology, and at Novartis, we remain focused on driving breakthrough science that can expand their potential for patients. Our agreement with BoomRay complements our growing radioligand therapy portfolio and reflects our strategy of combining external innovation with our cutting-edge research and development capabilities."
This partnership has the potential to not just accelerate the development of the new asset but also to pave the way for emerging therapies that can significantly impact clinical outcomes for cancer patients globally. As both BoomRay and Novartis embark on this exciting journey, the collaboration is expected to open new avenues for innovative treatment solutions, progressively aiming to address the critical unmet needs in oncology.
About BoomRay Pharmaceuticals Co., Ltd.: BoomRay is dedicated to pioneering radioligand therapies that address critical gaps in cancer treatment. Its core competencies encompass candidate discovery, radiochemistry, and clinical translation, all aimed at developing first-in-class or best-in-class treatment options for various cancer types. With a strong leadership and scientific team, BoomRay aspires to bring forth novel solutions that significantly improve patient outcomes around the world. The integration of expertise from Novartis enhances their mission and represents a hopeful future for oncology treatment options.
For more information about BoomRay Pharmaceuticals, visit http://www.boomray.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.